Hannah Butler
Family · Louisville, KYNPI 1114475795
Payments from drug & device makers
Across 158 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$394
- Novartis$330
- Bristol Myers Squibb$316
- AbbVie$238
- Genentech USA, Inc.$237
- Johnson & Johnson$133
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 20 | $394 |
| Novartis | 17 | $330 |
| Bristol Myers Squibb | 16 | $316 |
| AbbVie | 12 | $238 |
| Genentech USA, Inc. | 10 | $237 |
| Johnson & Johnson | 7 | $133 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| ADC Therapeutics America, Inc. | 6 | $111 |
| Genmab U.S., Inc. | 5 | $100 |
| Legend Biotech USA Inc. | 5 | $99 |
| AstraZeneca(2 entities) | 4 | $86 |
| Astellas Pharma US Inc | 3 | $81 |
| Rigel Pharmaceuticals, Inc. | 3 | $68 |
| Sanofi | 3 | $63 |
| Pfizer | 4 | $62 |
| Beone Medicines USA, Inc. | 4 | $60 |
| Beigene USA, Inc. | 2 | $53 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Gilead(2 entities) | 3 | $51 |
| Blueprint Medicines Corporation | 2 | $46 |
| GSK | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Adaptive Biotechnologies Corporation | 2 | $39 |
| Geron Corporation | 2 | $39 |
| Iovance Biotherapeutics, Inc. | 1 | $38 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Sobi, Inc | 1 | $30 |
| Karyopharm Therapeutics Inc. | 2 | $29 |
| Bayer | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Syndax Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Immunocore Limited | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$3,195 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 39 | $2,732 |
| Acyclovir | 174 | $2,400 |
| ValacyclovirValacyclovir Hcl | 19 | $903 |
| Ursodiol | 17 | $851 |
| Dexamethasone | 34 | $747 |
| Dapsone | 12 | $520 |
| Fluconazole | 14 | $459 |
| Omeprazole | 18 | $420 |
| Potassium Chloride | 32 | $406 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 80 | $292 |
| Levofloxacin | 18 | $173 |
| Pantoprazole Sodium | 24 | $135 |
| Azithromycin | 12 | $81 |
| Montelukast Sodium | 13 | $70 |
| Amlodipine Besylate | 21 | $67 |
Paid to pharmacies, not to this prescriber.
Other family in Louisville
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Shelley WaldmanLouisville$59K
- Esther MuhsLouisville$44K
- Barbra CaveLouisville$41K
- Kayla WilsonLouisville$40K
- Christin ThompsonLouisville$38K
- Wendi HallerLouisville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.